When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Shiga toxin - Wikipedia

   en.wikipedia.org/wiki/Shiga_toxin

   This is because Shiga toxin is usually taken in with contaminated food or water. [citation needed] The bacterial Shiga toxin can be used for targeted therapy of gastric cancer, because this tumor entity expresses the receptor of the Shiga toxin. For this purpose an unspecific chemotherapeutical is conjugated to the B-subunit to make it specific.

3. Urtoxazumab - Wikipedia

   en.wikipedia.org/wiki/Urtoxazumab

   E. coli Shiga-like toxin II B subunit: Clinical data; ATC code: ... The drug is designed to bind to a toxin of this bacterium, ... [2] References This page was last ...

4. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   non-small cell lung cancer: Anatumomab mafenatox [17] Fab: mouse: Tumor-associated glycoprotein 72 (TAG-72) non-small cell lung cancer: Andecaliximab [18] mab: chimeric: gelatinase B: gastric cancer or gastroesophageal junction adenocarcinoma Anetumab ravtansine [4] mab: human: mesothelin (MSLN) cancer Anifrolumab [4] Saphnelo: mab: human: IFN ...

5. Targeted therapy of lung cancer - Wikipedia

   en.wikipedia.org/.../Targeted_therapy_of_lung_cancer

   Approximately 98% of lung cancers are carcinoma, a term describing malignancies derived from transformed cells exhibiting characteristics of epithelium. About 2% of all lung cancers are non-carcinoma (mainly sarcoma, tumors of hematopoietic origin, or germ cell tumors. [5] These forms of lung cancer are usually treated differently from carcinomas.

6. Treatment of lung cancer - Wikipedia

   en.wikipedia.org/wiki/Treatment_of_lung_cancer

   Chemotherapy for NSCLC usually includes combination of two drugs (chemotherapy doublet), with one of the agents is cisplatin or carboplatin. In 2002, Schiller at al. published in the New England Journal of Medicine, a study that compared four chemotherapy regimens for advanced NSCLC, cisplatin and paclitaxel, cisplatin and gemcitabine, cisplatin and docetaxel, and carboplatin and paclitaxel. [14]

7. Hemolytic–uremic syndrome - Wikipedia

   en.wikipedia.org/wiki/Hemolytic–uremic_syndrome

   Shiga-toxin directly activates the alternative complement pathway and also interferes with complement regulation by binding to complement factor H, an inhibitor of the complement cascade. Shiga-toxin causes complement-mediated platelet, leukocyte, and endothelial cell activation, resulting in systemic hemolysis, inflammation and thrombosis.